Canada
EN FR

Africa

Asia Pacific

Europe

Middle East

North America

Latin America / Caribbean

South America

logo qulipta

  

Product Monograph
AbbVie Care Program
Important Safety Information
dosing and administration

QULIPTA® (atogepant tablets) is indicated for the prevention of migraine in adults who have at least 4 migraine days per month.1

QULIPTA: Convenient once-daily oral dosing1

 Episodic migraine 
The recommended dose is 10 mg, 30 mg, or 60 mg orally once daily.
The maximum recommended daily dose is 60 mg.

 

 Chronic migraine  
The recommended dose is 60 mg orally once daily.

 

 

Dosing modifications should be considered for concomitant use of specific drugs and for patients with hepatic or renal impairment.

Please see the QULIPTA Product Monograph for complete dosing and administration instructions including dose modifications for special populations and drug interactions.

 Episodic migraine 
The recommended dose is 10 mg, 30 mg, or
60 mg orally once daily.
The maximum recommended daily dose is
60 mg.

 

 Chronic migraine  
The recommended dose is 60 mg orally once daily.

 

Rx Pad_image_1x

 

 

Dosing modifications should be considered for concomitant use of specific drugs and for patients with hepatic or renal impairment.

Please see the QULIPTA Product Monograph for complete dosing and administration instructions including dose modifications for special populations and drug interactions.

Qulipta dosing

Available in 3 dosage strengths

Dosage strengths

Tablets not actual size.

Safety information

Click here for additional safety information and for a link to the Product Monograph discussing:

●Relevant warnings and precautions regarding patients with severe hepatic impairment, driving and operating machinery, pregnant and nursing women, and geriatrics.

●Conditions of clinical use, adverse reaction, drug interactions and dosing instructions.

Reference:

    1. QULIPTA Product Monograph. AbbVie Corporation.

OD: once daily.

 

For more information

For any questions related to QULIPTA, you can contact AbbVie Medical Information at 1 844 241-5011.

 

QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.

 

OD: once daily.

 

For more information

For any questions related to QULIPTA, you can contact AbbVie Medical Information at
1 888 241-5011.

 

QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.

 

CA-QLP-240063A / OC24

This website is intended for Canadian Healthcare Professionals

Copyright® 2022 AbbVie Corporation. Canada. 

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.